Alzheimer’s disease (AD) is a complex and heterogeneous condition requiring early detection and intervention. Biomarkers contribute to diagnostic processes and real-world evidence (RWE) outcomes. Robust real-world data can drive insights to bridge disease, policy, clinical trials, and access gaps in the diagnosis and treatment of AD, providing valuable objective endpoints.

This study was run to determine if a racial disparity exists in biomarker testing for NSCLC (non-small cell lung cancer) patients. Jared Safran, PharmD, MS, Russell Robbins, MD, MBA, Maggie Mendes, Douglas Londono, PhD, Grace Kane, MS. Healthcare is evolving into precision medicine or what the FDA refers to as personalized medicine1. This targeted approach…

This study was run to evaluate whether provider specialty is a driver for biosimilar adoption, defined as adoption probability difference (APD). Diane Faraone, PharmD, Russell Robbins, MD, MBA, Grace Kane, MS, Douglas Londono, PhD.  The US biologics market has significantly expanded in recent years; projected to reach $62 billion in prescription drug spend by 2025. Biosimilar…

Study is to assess the SARS-CoV-2 antibody levels over time (2021-2022), measured with the Elecsys Anti-SARS-COV-2 S assay, in the real-world setting, and assess the association between them and subsequent COVID-19 outcomes. Jin, Yue; Yang, Fei; Rank, Christopher; Letovsky, Stanley; Ramge, Peter and Jochum, Simon presented a poster during ISPE 2024. The objective of this…

PurpleLab was selected to present a poster at PMSA 2024 on imputing SDOH information on pharmacy claims. This study was centered around prescription fill rates of Semaglutides in the adolescent population. In December of 2022, the FDA approved adolescents BMI at or above the 95th percentile eligible for a Semaglutide prescription. PurpleLab used a combination…

Higher SARS-COV-2 spike antibody levels are associated with reduced risk of subsequent symptomatic and severe COVID-19. Jin, Yue; Yang, Fei; Rank, Christopher; Letovsky, Stanley; Ramge, Peter and Jochum, Simon from Roche Information Solutions, Roche Diagnostics GmbH, Roche Diagnostics Solutions, and Roche Diagnostics International presented a poster during ISPOR 2024. The objective was to assess the…

Impact of Applying SDOH on Prescription Fill Rate Analysis Life Sciences This whitepaper highlights the significance of understanding prescription rejection rates, particularly for specialty pharmacy medications, and the role of plan design and social determinants of health (SDOH) in determining eligibility and out-of-pocket costs for patients.   Traditional analyses focusing solely on demographics like age and…

Although biologics and biosimilar drugs only represent 2% of U.S. prescription volume, these naturally sourced medications have recently become the focus of much discussion across healthcare channels. Biologics – often considered specialty drugs – have accounted for as much as 37% of drug spending in a single year.

To create a market assessment, more and more brand strategists are moving towards the use of RWD and RWE. In this blog, we walk through a hypothetical example – sizing the market for Hemophilia A – doing just that.  Creating a market assessment is a critical step in commercializing a new drug. This is because…